6.
Boros B, Schoch K, Kreple C, Miller T
. Antisense Oligonucleotides for the Study and Treatment of ALS. Neurotherapeutics. 2022; 19(4):1145-1158.
PMC: 9587169.
DOI: 10.1007/s13311-022-01247-2.
View
7.
Takahashi F, Takei K, Tsuda K, Palumbo J
. Post-hoc analysis of MCI186-17, the extension study to MCI186-16, the confirmatory double-blind, parallel-group, placebo-controlled study of edaravone in amyotrophic lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degener. 2017; 18(sup1):32-39.
DOI: 10.1080/21678421.2017.1361442.
View
8.
De Marchi F, Tondo G, Corrado L, Menegon F, Aprile D, Anselmi M
. Neuroinflammatory Pathways in the ALS-FTD Continuum: A Focus on Genetic Variants. Genes (Basel). 2023; 14(8).
PMC: 10454262.
DOI: 10.3390/genes14081658.
View
9.
Lunetta C, Moglia C, Lizio A, Caponnetto C, Dubbioso R, Giannini F
. The Italian multicenter experience with edaravone in amyotrophic lateral sclerosis. J Neurol. 2020; 267(11):3258-3267.
DOI: 10.1007/s00415-020-09993-z.
View
10.
Liu X, Henty-Ridilla J
. Multiple roles for the cytoskeleton in ALS. Exp Neurol. 2022; 355:114143.
PMC: 10163623.
DOI: 10.1016/j.expneurol.2022.114143.
View
11.
Jin J, Zhong X
. ASO drug Qalsody (tofersen) targets amyotrophic lateral sclerosis. Trends Pharmacol Sci. 2023; 44(12):1043-1044.
PMC: 10841252.
DOI: 10.1016/j.tips.2023.08.008.
View
12.
Tian Y, Wang Y, Jablonski A, Hu Y, Sugam J, Koglin M
. Tau-tubulin kinase 1 phosphorylates TDP-43 at disease-relevant sites and exacerbates TDP-43 pathology. Neurobiol Dis. 2021; 161:105548.
DOI: 10.1016/j.nbd.2021.105548.
View
13.
Klim J, Williams L, Limone F, Guerra San Juan I, Davis-Dusenbery B, Mordes D
. ALS-implicated protein TDP-43 sustains levels of STMN2, a mediator of motor neuron growth and repair. Nat Neurosci. 2019; 22(2):167-179.
PMC: 7153761.
DOI: 10.1038/s41593-018-0300-4.
View
14.
. A post-hoc subgroup analysis of outcomes in the first phase III clinical study of edaravone (MCI-186) in amyotrophic lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degener. 2017; 18(sup1):11-19.
DOI: 10.1080/21678421.2017.1363780.
View
15.
Becker L, Huang B, Bieri G, Ma R, Knowles D, Jafar-Nejad P
. Therapeutic reduction of ataxin-2 extends lifespan and reduces pathology in TDP-43 mice. Nature. 2017; 544(7650):367-371.
PMC: 5642042.
DOI: 10.1038/nature22038.
View
16.
Soares P, Silva C, Chavarria D, Silva F, Oliveira P, Borges F
. Drug discovery and amyotrophic lateral sclerosis: Emerging challenges and therapeutic opportunities. Ageing Res Rev. 2022; 83:101790.
DOI: 10.1016/j.arr.2022.101790.
View
17.
Neumann M, Sampathu D, Kwong L, Truax A, Micsenyi M, Chou T
. Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science. 2006; 314(5796):130-3.
DOI: 10.1126/science.1134108.
View
18.
Amado D, Robbins A, Smith A, Whiteman K, Chillon Bosch G, Chen Y
. AAV-based delivery of RNAi targeting Ataxin-2 improves survival, strength, and pathology in mouse models of rapidly and slowly progressive sporadic ALS. bioRxiv. 2024; .
PMC: 10862885.
DOI: 10.1101/2024.01.31.578314.
View
19.
Pulst S, Nechiporuk A, Nechiporuk T, Gispert S, Chen X, Lopes-Cendes I
. Moderate expansion of a normally biallelic trinucleotide repeat in spinocerebellar ataxia type 2. Nat Genet. 1996; 14(3):269-76.
DOI: 10.1038/ng1196-269.
View
20.
Melamed Z, Lopez-Erauskin J, Baughn M, Zhang O, Drenner K, Sun Y
. Premature polyadenylation-mediated loss of stathmin-2 is a hallmark of TDP-43-dependent neurodegeneration. Nat Neurosci. 2019; 22(2):180-190.
PMC: 6348009.
DOI: 10.1038/s41593-018-0293-z.
View